Kedrion's QIVIGY® Receives Orphan Drug Designation for Rare Neurological Disorder#United_States#Fort_Lee,_NJ#Kedrion_Biopharma#QIVIGY#Stiff_Person_Syndrome
Kedrion's QIVIGY® Receives Orphan Drug Designation for Rare Neurological Disorder
Kedrion Biopharma's QIVIGY® has achieved Orphan Drug Designation from the FDA for treating Stiff Person Syndrome, a rare neurological condition.
third-news.com
September 22, 2026 at 1:42 PM
Kedrion's QIVIGY® Receives Orphan Drug Designation for Rare Neurological Disorder#United_States#Fort_Lee,_NJ#Kedrion_Biopharma#QIVIGY#Stiff_Person_Syndrome